Methylprednisolone

Limits on what this shows

• Key negative/null findings: None located specific to methylprednisolone; the neuronal review is a class-level synthesis, not a methylprednisolone-specific dataset.
• At-risk subgroups: None established with drug-specific human data.
• Counter-evidence on record: The in vitro thymocyte data are drug-specific but limited to isolated immune cells at defined concentrations, not whole-organism human tissue; extrapolation to systemic "mitochondrial damage" in patients is not supported at this tier.

Regulatory status

Not addressed in the label.

Population evidence

None in humans directly measuring mitochondrial structure/function from methylprednisolone exposure.

Mechanism

Named and drug-specific (in vitro): methylprednisolone added to rat thymocytes inhibited Na±/K±-ATPase- and Ca2±-ATPase-linked oxygen consumption within under 30 seconds — too fast for classic genomic receptor signaling, indicating a direct plasma-membrane effect (see overlap with ATP production entry below). A separate literature review (glucocorticoids as a class, chiefly dexamethasone/corticosterone/cortisol/hydrocortisone/prednisone, not methylprednisolone specifically) describes suppressed mitophagy (via PGC1α repression), abnormal fission/fusion, and reduced mitochondrial biogenesis gene expression in neurons.

Framing caution

Do not present as established human mitochondrial toxicity; this is cell-level mechanistic evidence only.

Limits on what this shows

• Key negative/null findings: Acute rat dosing showed no change in lipid peroxidation; chronic rat dosing showed no change in TRAP — the effect is marker- and duration-specific, not a uniform shift in either direction.
• At-risk subgroups: Patients on prolonged/chronic dosing, per the rat data showing harm only at 30 days, not acutely.
• Counter-evidence on record: The human pediatric ITP finding (improvement) plausibly reflects disease resolution (ITP itself is associated with elevated oxidative stress) rather than a direct antioxidant effect of the drug — a textbook confounding-by-indication concern (Hard Rule 6), since there was no non-steroid comparator arm.

Regulatory status

Not addressed in the label.

Population evidence

Human: 30 children with acute immune thrombocytopenia given methylprednisolone 30 mg/kg ×3 days then 20 mg/kg ×4 days — total antioxidant capacity, paraoxonase and arylesterase activity rose, and total oxidant status/oxidative stress index fell after 7 days, versus pre-treatment and versus 30 healthy controls at baseline.

Mechanism

Named, drug-specific, dose/duration-dependent (rat lung, 40 Wistar rats): acute single-dose methylprednisolone (50 mg/kg IP) raised total radical-trapping antioxidant parameter (TRAP) 20% at 24 h (reduced oxidative stress) with no change in lipid peroxidation; chronic dosing (6 mg/kg/day ×30 days) showed no TRAP change but 38% higher lipid peroxidation (increased oxidative damage). Authors: "acute use...is beneficial to lung tissue, whereas their chronic use is not."

Framing caution

Genuinely conflicting; do not present as either "methylprednisolone is an antioxidant" or "methylprednisolone causes oxidative stress" on a consumer surface. Direction depends on acute versus chronic exposure and tissue studied.

Limits on what this shows

• Key negative/null findings: None located specific to methylprednisolone in either direction.
• At-risk subgroups: None established with drug-specific human data.
• Counter-evidence on record: Elevated ferritin has separately been studied in COVID-19 patients receiving methylprednisolone, but there as a baseline prognostic inflammatory marker used to select candidates for treatment, not as evidence the drug itself raises or lowers iron stores; that literature was not used to support this entry.

Regulatory status

Not addressed in the label.

Population evidence

None in humans on methylprednisolone directly.

Mechanism

Named, but class-level (rats given IV corticosterone daily for 7 days, and the human hepatocyte line HL7702 treated with hydrocortisone): both upregulated iron regulatory protein 1 (IRP-1) and transferrin receptor-1 and produced liver iron accumulation, while ferritin expression fell. Effects were blocked by the glucocorticoid-receptor antagonist RU486, and further reduced by co-inhibiting STAT5, implicating glucocorticoid receptor and phospho-STAT5 binding at the IRP-1 gene promoter — a mechanism methylprednisolone shares in principle as a glucocorticoid-receptor agonist, though it was not itself tested.

Framing caution

This points toward retention, not deficiency. A consumer claim of "methylprednisolone depletes iron" is not supported by any evidence found; if anything, the mechanistic direction runs the other way, so iron supplementation on the basis of this drug alone would not be appropriate.

Limits on what this shows

• Why no grade: Both conditions in the dual test were met: (1) no Tier B or Tier C evidence was found to support even a yellow grade — the one controlled trace-element study located (32 RA patients) found corticosteroids as a treatment category produced no significant change in serum copper; (2) no circulating consumer nutrient-depletion source reviewed for this dossier listed copper among the nutrients corticosteroids are claimed to deplete. This is a genuine literature gap, not a safety finding.

Search channels tried

Multiple phrasings across PubMed, DailyMed, NCBI Bookshelf, and general web search for "methylprednisolone copper," "corticosteroid ceruloplasmin," and related terms. One directly relevant PubMed record (zinc/copper status in corticosteroid-treated RA patients) could not be opened after repeated bot-verification blocks; see source list access notes.

Limits on what this shows

• Key negative/null findings: None located specific to methylprednisolone; no non-steroid comparator arm in this single-cohort design.
• At-risk subgroups: Patients receiving high cumulative-dose IV pulse regimens; disease-specific (Graves' ophthalmopathy) population, so generalization to other indications and to oral dosing is uncertain.
• Counter-evidence on record: Single center, n=20, one disease population, one dosing regimen; before/after design without an untreated comparator arm, so disease activity itself is a possible confounder (Hard Rule 6 caution).

Regulatory status

Not addressed in the regulatory label.

Population evidence

Prospective observational study, 20 patients with Graves' ophthalmopathy, methylprednisolone 0.5 g IV weekly × 6 weeks then 0.25 g IV weekly × 6 weeks (cumulative 4.5 g over 12 weeks): Shannon and Simpson diversity indices decreased; Firmicutes/Bacteroidetes ratio increased; Faecalibacterium and Prevotella (short-chain-fatty-acid producers) decreased while Streptococcus increased; short-chain fatty acid-producing capacity decreased; fecal 5-hydroxytryptamine increased.

Mechanism

Not fully elucidated in the source; glucocorticoid immunomodulation and altered gut epithelial/mucin signaling are proposed pathways (see overlap note with a dexamethasone animal study below, which is class-level, not this drug).

Framing caution

This does not establish "leaky gut" or a specific probiotic remedy; it is a compositional shift in a small, single-disease cohort on high cumulative IV dosing, not shown yet in oral or lower-dose regimens.

Limits on what this shows

• Key negative/null findings: None specific to methylprednisolone.
• At-risk subgroups: None established.
• Counter-evidence on record: This is endogenous cortisol excess (a distinct physiological state from exogenous methylprednisolone dosing), so extrapolation is class-level/mechanistic only, per Hard Rule 2's caution against mistaking a drug's own hormonal biology for a nutrient/oxygen-delivery deficiency.

Regulatory status

Not addressed in the label; anemia is not a labeled adverse reaction of methylprednisolone.

Population evidence

Human, but endogenous disease rather than drug exposure: 13 patients with active Cushing syndrome versus 13 of the same patients after surgical remission showed erythrocytosis (increased red cell mass, normal HbF) during the active hypercortisolemic phase, with a stress-progenitor CD34+ cell phenotype.

Mechanism

Class-level: glucocorticoid receptor activity supports expansion of immature erythroid progenitors in cooperation with the erythropoietin receptor pathway, a mechanism distinct from methylprednisolone's approved indications and not tested with this drug specifically.

Framing caution

There is no credible mechanism or data suggesting methylprednisolone impairs oxygen delivery; consumer claims linking corticosteroid "fatigue" to reduced oxygen-carrying capacity are not supported by anything found in this review.

Limits on what this shows

• Key negative/null findings: Protein-, RNA- and DNA-synthesis-related oxygen consumption were not significantly affected in the thymocyte study, showing the effect is selective to ion-pump-linked respiration, not a global shutdown of cellular energy metabolism.
• At-risk subgroups: None established in humans.
• Counter-evidence on record: Findings are limited to isolated immune and tumor cell systems at experimentally defined concentrations; no human whole-body energy-expenditure or muscle ATP data were located for methylprednisolone.

Regulatory status

Not addressed in the label.

Population evidence

None in whole-organism humans.

Mechanism

Named and drug-specific (in vitro): in quiescent and Concanavalin-A-stimulated rat thymocytes, methylprednisolone dose-dependently inhibited Na±/K±-ATPase-dependent oxygen consumption (and, in stimulated cells, Ca2±-ATPase-dependent consumption) within under 30 seconds, too fast to be gene-transcription-mediated; protein-, RNA-, and DNA-synthesis-linked oxygen consumption were largely spared. A companion study in Ehrlich ascites tumor cells found methylprednisolone instantly and dose-dependently inhibited oxygen consumption and blocked calcium-ionophore-triggered intracellular calcium rise, attributed to a direct membrane-permeability effect.

Framing caution

This is real, drug-specific, mechanistic evidence, but it does not establish human "fatigue from low ATP." It shares its underlying source material with the mitochondrial burden entry above; see the overlap map.